Enliven Therapeutics, Inc.

NASDAQ:ELVN

17.77 (USD) • At close May 30, 2025
Bedrijfsnaam Enliven Therapeutics, Inc.
Symbool ELVN
Munteenheid USD
Prijs 17.77
Beurswaarde 871,961,461
Dividendpercentage 0%
52-weken bereik 13.3 - 30.03
Industrie Biotechnology
Sector Healthcare
CEO Mr. Samuel S. Kintz M.B.A.
Website https://www.enliventherapeutics.com

An error occurred while fetching data.

Over Enliven Therapeutics, Inc.

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a

Vergelijkbare Aandelen

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)